Conference Coverage

A primer on pediatric acne


 

EXPERT ANALYSIS FROM AAD SUMMER ACADEMY

Dr. Zaenglein added that hormonal therapies should be avoided within 3 years of menarche if possible.

Dr. Zaenglein is on the advisory board for Galderma, Valeant, and Promius; a speaker for Galderma; and involved in clinical trials with Galderma, Medicis, and Valeant.

nmiller@frontlinemedcom.com

On Twitter @NaseemSMiller

Pages

Recommended Reading

Identifying pediatric emergencies involving fever and rash
MDedge Dermatology
Hemangiomas don’t always resolve, so refer
MDedge Dermatology
The Relationship Between Obesity and Psoriasis in the Pediatric Population: Implications and Future Directions
MDedge Dermatology
What Is Your Diagnosis? PHACE Syndrome
MDedge Dermatology
Five pearls guide pediatric psoriasis systemic therapy
MDedge Dermatology
Neonatal Skin: A Dynamic Adaptation Process
MDedge Dermatology
Dexamethasone improves outcomes for infants with bronchiolitis, atopy history
MDedge Dermatology
PTPB formaldehyde resin proposed as pediatric allergen of the year
MDedge Dermatology
Intensive ‘Boot Camp’ protocol improves kids’ atopic dermatitis
MDedge Dermatology
‘Eczema coxsackium’ cutaneous eruptions characterized
MDedge Dermatology